By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.
Location: United States
Total raised: $127M
Investors 2
| Date | Name | Website |
| 09.03.2024 | ARCH Ventu... | archventur... |
| 10.01.2024 | Alpha Wave... | alphawaveg... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.09.2026 | Series B | $70M | - |
| 05.01.2024 | Seed | $57M | - |
Mentions in press and media 5
| Date | Title | Description |
| 09.09.2026 | Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update | NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 09.01.2024 | Why Carta’s public battle might be a private markets nightmare | To say the Carta news that broke over the weekend has caused a furor in the startup world is an understatement. The accusation that the cap table management and software unicorn was using customers’ confidential data to bolster its own busi... |
| 05.01.2024 | Moonwalk Biosciences Closes $57M in Seed and Series A Financing | Moonwalk Biosciences, a San Francisco and San Diego, CA-based genomic medicine company, raised $57M in Seed and Series A funding. The rounds saw participation from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Vent... |
| - | Moonwalk Biosciences | “Pioneering precision epigenetic medicines We are hiring passionate, talented moonwalkers. See our open roles. Walk with Us Our science By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy... |
| - | Moonwalk Biosciences | “By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.” |